Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
February 4, 2026Pamplona/MadridIn recruitmentEarly phase
IOV-LUN-202 Clinical trial of autologous tumor-infiltrating lymphocytes (LN-145) in patients with metastatic non-small cell lung cancer
The objective of this study is to test a new investigational treatment for participants with non-small cell lung cancer. -
February 4, 2026PamplonaIn recruitment
UCART20X22-01 Clinical trial to evaluate UCART20x22 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
This study is being conducted to determine: - the safe and tolerable dose of UCART20x22 - the efficacy of UCART20x22 in the treatment of NHLB - how long it takes for the body to eliminate UCART20x22 - how much UCART20x22 reaches the bloodstream This study will also test the safety and effectiveness of different lymphodepletion regimens for patients receiving UCART20x22. Lymphodepletion is a type of therapy that decreases the number of your T cells to make room for the UCART20x22 cells. Three dru... -
February 2, 2026Pamplona/MadridIn recruitmentEarly phase
-
January 28, 2026Pamplona/MadridIn recruitmentEarly phase
ASTX030-01 Estudio de ASTX030 (cedazuridina en combinación con azacitidina) en los SMD, la LMMC o la LMA
The purpose of this study is to analyze the levels of the experimental drug ASTX030 in your blood, evaluate the safety and tolerability of the drugs, and find out how participants respond to the drug. -
January 28, 2026Pamplona/MadridIn recruitmentEarly phase
BO45287 Open-label, multicenter phase Ib study to evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.
The purpose of this study is to test different doses of mosunetuzumab to see if it is safe and to learn how the body processes the drug. Mosunetuzumab will be evaluated in combination with pirtobrutinib, which is another drug currently used to treat CLL. -
January 28, 2026Pamplona/MadridIn recruitment
RLY-2608-102 Phase III clinical trial to evaluate RLY-2608 fulvestrant compared to capivasertib fulvestrant as a treatment for locally advanced or metastatic breast cancer.
The primary objective is to compare the efficacy of RLY-2608 Fulvestrant relative to Capivasertib Fulvestrant by evaluating PFS in the overall population and in the kinase population using BICR. -
January 26, 2026Pamplona/MadridIn recruitment
5-STAR 1-01 Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 in advanced solid tumors.
The primary objective is to determine the safety and tolerability of TUB-030 and the maximum tolerated dose (MTD), if observed, of TUB-030 as a single agent in patients with advanced solid tumors. -
January 22, 2026Pamplona/MadridIn recruitmentEarly phase
D7987C00001 Clinical trial to evaluate the efficacy and safety of new immunomodulators as monotherapy and in combination with antineoplastic agents in patients with advanced hepatobiliary cancer (GEMINI-HCC)
The objective of this trial is to obtain more information about the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of MEDI5752, and also to better understand the disease being studied and the associated health problems. -
January 22, 2026Pamplona/MadridIn recruitment
-
January 19, 2026Pamplona/MadridIn recruitment
ART0380C001 Trial of ART0380 as an oral treatment and with gemcitabine in patients with advanced or metastatic solid tumors
The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be given together with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be given to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can the study pro...